Complementary plant-based medicine is used in developing countries to address healthcare challenges and limited access to conventional medicines. Moringa oleifera has been studied for its anti-diabetic properties, but human studies are limited. This study evaluated the long-term effect of daily M. oleifera leaf powder consumption on glycemic control in Sahrawi women with type 2 diabetes. A 3-month unblind randomized controlled trial was conducted with 45 Sahrawi women treated with oral glucose-lowering drugs. Participants were divided into two groups: an experimental group (30 women) and a control group (15 women). The experimental group received 10 g of M. oleifera leaf powder daily, while the control group did not consume Moringa. Anthropometric and glycemic parameters (fasting glucose and glycated hemoglobin) were measured at baseline and after 3 months. A proximate and phenolic analysis of plant material was also performed. M. oleifera leaves were rich in protein, fiber, and quercetin- and kaempferol-glucosides. After 3 months, the experimental group showed a significant reduction in body fat (-1.5 %, 95 %CI: −2.5, −0.5, p < 0.001) and improved glycated hemoglobin levels (-0.59 %, 95 %CI: −0.93, −0.25, p < 0.001), while these parameters remained unchanged in the control group. In conclusion, daily M. oleifera consumption, alongside drug therapy, may improve glycemic control in type 2 diabetes. Further studies are recommended to confirm these findings.

Moringa oleifera Leaf Powder Enhances Glycemic Control in Sahrawi Women with Type 2 Diabetes: Findings from a 3-Month Unblinded Randomized Controlled Trial / A. Leone, S. Di Lello, S. Bertoli, S. Ravasenghi, R. De Amicis, F. Menichetti, G. Fico, L. Santagostini, B. Mohamed-Iahdih, S.M.L. Saleh, A. Battezzati. - In: PHARMANUTRITION. - ISSN 2213-4344. - 31:(2025), pp. 100434.1-100434.7. [10.1016/j.phanu.2025.100434]

Moringa oleifera Leaf Powder Enhances Glycemic Control in Sahrawi Women with Type 2 Diabetes: Findings from a 3-Month Unblinded Randomized Controlled Trial

A. Leone
Primo
;
S. Bertoli;S. Ravasenghi;R. De Amicis;F. Menichetti;G. Fico;L. Santagostini;A. Battezzati
2025

Abstract

Complementary plant-based medicine is used in developing countries to address healthcare challenges and limited access to conventional medicines. Moringa oleifera has been studied for its anti-diabetic properties, but human studies are limited. This study evaluated the long-term effect of daily M. oleifera leaf powder consumption on glycemic control in Sahrawi women with type 2 diabetes. A 3-month unblind randomized controlled trial was conducted with 45 Sahrawi women treated with oral glucose-lowering drugs. Participants were divided into two groups: an experimental group (30 women) and a control group (15 women). The experimental group received 10 g of M. oleifera leaf powder daily, while the control group did not consume Moringa. Anthropometric and glycemic parameters (fasting glucose and glycated hemoglobin) were measured at baseline and after 3 months. A proximate and phenolic analysis of plant material was also performed. M. oleifera leaves were rich in protein, fiber, and quercetin- and kaempferol-glucosides. After 3 months, the experimental group showed a significant reduction in body fat (-1.5 %, 95 %CI: −2.5, −0.5, p < 0.001) and improved glycated hemoglobin levels (-0.59 %, 95 %CI: −0.93, −0.25, p < 0.001), while these parameters remained unchanged in the control group. In conclusion, daily M. oleifera consumption, alongside drug therapy, may improve glycemic control in type 2 diabetes. Further studies are recommended to confirm these findings.
Moringa oleifera; Diabetes; Humans; Glucose; HbA1c
Settore MEDS-08/C - Scienza dell'alimentazione e delle tecniche dietetiche applicate
Settore BIOS-06/A - Fisiologia
Settore BIOS-01/D - Biologia farmaceutica
Settore CHEM-01/B - Chimica dell'ambiente e dei beni culturali
2025
5-feb-2025
Article (author)
File in questo prodotto:
File Dimensione Formato  
2025 Leone et al. - Moringa Glycemic Control T2DM.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 930.86 kB
Formato Adobe PDF
930.86 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1143135
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact